NCT07342803

Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma Patients

A Multicenter, Randomized, Double-Blind, Active Drug and Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in the Treatment of Patients With Moderate to Severe Persistent Allergic Asthma.

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: Longbio Pharma · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, randomized, masked, active and placebo controlled, Phase II clinical study to evaluate the efficacy, safety, and pharmacokinetics of LP-003 injection in adult patients with moderate to severe persistent allergic asthma.

Conditions

• Allergic Asthma

Interventions

Type	Name	Description
BIOLOGICAL	LP-003 Injection	s.c. injection, Q12W
BIOLOGICAL	Omalizumab	s.c. injection, Q4W
BIOLOGICAL	Placebo	s.c. injection, Q4W

Timeline

• Start date: 2025-01-25
• Primary completion: 2027-12-28
• Completion: 2029-09-30
• First posted: 2026-01-15
• Last updated: 2026-01-15

Locations

1 site across 1 country: China